Journal of Hepatology, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 1, 2024
Language: Английский
Clinical and Molecular Hepatology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 9, 2025
Alcohol represents a leading burden of disease worldwide, including alcohol use disorder (AUD) and alcohol-related liver (ALD). We aim to assess the global AUD, ALD, alcohol-attributable primary cancer between 2000-2021. registered regional trends using data from Global Burden Disease 2021 Study, largest most up-to-date epidemiology database. estimated annual percent change (APC) its 95% confidence interval (CI) changes in age-standardized rates over time. In 2021, there were 111.12 million cases 3.02 132,030 cancer. Between 2000 was 14.66% increase 38.68% 94.12% prevalence. While prevalence rate for increased (APC: 0.59%, [CI] 0.52 0.67%) these years, it decreased ALD -0.71%, CI -0.75 -0.67%) AUD -0.90%, -0.94 -0.86%). There significant variation by region, socioeconomic development level, sex. During last years (2019-2021), prevalence, incidence, death greater extent females. Given high cancer, urgent measures are needed prevent them at both national levels.
Language: Английский
Citations
5
The Lancet. Gastroenterology & hepatology, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 1, 2025
Language: Английский
Citations
3
Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 14, 2025
ABSTRACT Background There are no FDA‐approved therapies for alcohol‐associated liver disease (ALD). Preclinical studies indicate that blocking IL‐23/IL‐17 signalling may reverse injury. Guselkumab, an IL‐23‐specific antibody approved psoriasis, be beneficial ALD. Aims We aimed to assess the safety and tolerability of guselkumab in patients with Methods This phase‐1 dose‐escalation study included ≥ 2 DSM‐5 criteria alcohol use disorder, significant steatosis (MRI‐PDFF 8%) MRE < 3.63 kPa (to exclude advanced disease). Guselkumab was given subcutaneously on Days 1 29 30, 70 or 100 mg dose cohorts. Primary endpoints were adverse events (AEs) dose‐limiting toxicity. Results enrolled 13 (three 30 mg, three seven mg). Eleven completed two early discontinued group. Of them, 77% men, median age 53 [IQR 49–61] years. The MRI‐PDFF 18.4% 8.4%–34.0%] 2.5 [2.2–2.6] kPa, respectively. most frequent AEs hyperuricemia (13%, mild only) elevated lipase (11%, moderate). serious variations enzymes. a suppression peripheral interleukin (IL)‐17, IL‐23, IL‐1b TNF‐α groups, decrease consumption over time (AUDIT‐C: 6 [3–7] vs. 5 [1–6], p = 0.023). Conclusions is safe doses up reduce inflammation markers These findings support further phase evaluate efficacy ALD, particularly severe phenotypes.
Language: Английский
Citations
2
Nature Reviews Disease Primers, Journal Year: 2025, Volume and Issue: 11(1)
Published: March 6, 2025
Language: Английский
Citations
2
Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 15, 2025
The recent re-naming and reclassification of 'non-alcoholc fatty liver disease (NAFLD)' to steatotic (SLD) subcategories aims clarify the different aetiologies associated with fat accumulation, particularly alcohol consumption and/or metabolic dysfunction [1]. A novel entity, coined as 'metabolic related/associated (MetALD)' was introduced capture individuals whose intake exceeds traditional NAFLD thresholds but not yet meet alcohol-related (ALD) shift in terminology highlights complexity between on pathophysiology, natural course treatment implications SLD. Accurate quantification is therefore crucial. However, current estimations rely solely patients' self-report, where underreporting common leading misclassification. An objective biomarker pivotal providing an accurate assessment individual's drinking pattern. Phosphatidylethanol (PEth) levels blood a promising that has garnered significant attention field research. Being abnormal phospholipid only formed presence ethanol, it easily measured blood, also long detection window lasting for 2–4 weeks. Tavaglione et al. conducted cross-sectional study compare PEth other indirect biomarkers diagnosis MetALD versus dysfunction-associated (MASLD) 374 subjects who were obese (body mass index [BMI] ≥ 25 kg/m2) imaging-confirmed SLD (magnetic resonance imaging-proton density fraction or transient elastography). Alcohol use quantified using questionnaire (AUDIT score Lifetime Drinking History) DSM-V criteria. shown have high diagnostic accuracy (AUROC 0.81, 95% CI 0.73–0.89) optimal cut-off level ng/mL. It showed superiority over including aspartate aminotransferase/alanine aminotransferase ratio, mean corpuscular volume, gamma glutamyltransferase ALD/NAFLD (p < 0.05) diagnosing cohort positive linear correlation daily AUDIT demonstrated [2]. This paper provides timely insight into role redefining results align compelling evidence affirming utilising predict quantity [3], joint position statement recommend its [4]. Given derived from human erythrocytes, precision measurements may be impacted by conditions such cirrhosis, anaemia, hypersplenism [5]. Similarly, variations observed patients engaging binge those chronic heavy consumption, well various BMIs. Delving deeper these aspects through additional research can enhance validation PEth's clinical utility. Variability across diverse ethnic groups presents valuable opportunity future new classification comprehension conditions, their epidemiology, diagnosis, progression management strategies. Incorporating improve validity applicability this system, ultimately enhancing decision-making patient outcomes. Karen Cheuk-Ying Ho: writing – original draft. Lung-Yi Mak: review editing, supervision. article linked al papers. To view articles, visit https://doi.org/10.1111/apt.18506 https://doi.org/10.1111/apt.70006. Data sharing applicable no datasets generated analysed during study.
Language: Английский
Citations
1
Journal of Clinical and Experimental Hepatology, Journal Year: 2025, Volume and Issue: 15(3), P. 102500 - 102500
Published: Jan. 5, 2025
Language: Английский
Citations
0
Clinical and Molecular Hepatology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 21, 2025
Language: Английский
Citations
0
Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 23, 2025
We deeply appreciate the insightful letter from Liu and He et al., which highlights their analysis of global burden metabolic dysfunction-associated steatotic liver disease (MASLD)-related cancer using Global Burden Disease Study (GBD) 2021 database [1]. The similarities between findings our observations on rising MASLD-related in United States underscore importance this issue [2]. data trends cancer, particularly notable increases incidence mortality, are highly significant. Prior studies same also emphasised disease-related with increasing age-standardised rates for both alcohol-associated (ALD) (APC: 0.26%, 95% CI 0.22%–0.30%) MASLD 0.62%, 0.58%–0.67%) [3, 4]. non-overlapping confidence intervals support assertion, as noted by that is a primary driver disease, evidenced projections through 2050 However, several limitations to GBD methodology warrant consideration [5]. For example, alcohol use frequently underreported, could result some cases being reclassified dysfunction (MetALD) or ALD [6, 7]. A comprehensive history, including recent lifetime intake, essential ensure accurate prognosis management. Consideration alcohol's impact syndrome criteria, reassessing over time, addressing challenges underreporting biomarkers, validated questionnaires collateral information [6]. Furthermore, since 2024, Resmetirom has received conditional approval treating MASH, while treatment advancements have lagged behind, suggesting future may increase more than [8, 9]. further underscores critical need incorporate demographic factors, population aging, into strategies preventing managing cancer. This extends ALD-associated disorder shows similar prevalence general [10]. Such insights can guide development tailored public health resource allocation effectively address these populations' unique needs, will translate prevention Further refinement large-scale databases accurately quantify aetiology-specific contributions, globally, informing efforts, target populations, reduce mortality. Pojsakorn Danpanichkul: writing – original draft. Donghee Kim: review editing. Markos Kalligeros: Amit G. Singal: Ju Dong Yang: Karn Wijarnpreecha: Yang consults AstraZeneca, Eisai, Exact Sciences FujiFilm Medical Sciences. Singal served consultant advisory boards Genentech, Exelixis, Bayer, Elevar, Boston Scientific, Sirtex, Histosonics, Sciences, Roche, Abbott, Glycotest, Freenome GRAIL. authors' declarations personal financial interests unchanged those article linked Danpanichkul al papers. To view articles, visit https://doi.org/10.1111/apt.18473 https://doi.org/10.1111/apt.18510. authors nothing report.
Language: Английский
Citations
0
Journal of Hepatology, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 1, 2025
Language: Английский
Citations
0
Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 15, 2025
We thank Ho and Mak for their positive comments on our recently published work, in which we demonstrate that phosphatidylethanol (PEth) is an accurate, quantitative, objective, blood-based alcohol biomarker diagnosing the newly defined metabolic dysfunction alcohol-related liver disease (MetALD) [1]. Leveraging a well-characterised United States (U.S.) cohort of 374 community-dwelling individuals with overweight or obesity steatotic (SLD) assessed through advanced magnetic resonance imaging (MRI) techniques [2], showed PEth exhibited robust diagnostic accuracy differentiating MetALD from dysfunction-associated (MASLD) (AUROC 0.81, 95% CI 0.73–0.89) optimal cut-off 25 ng/mL, outperformed indirect biomarkers, including aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio, gamma glutamyltransferase (GGT), mean corpuscular volume (MCV) ALD/non-alcoholic fatty index (ANI). abnormal cellular membrane phospholipid formed human erythrocytes exclusively during ingestion. Specifically, synthesised phosphatidylcholine transphosphatidylation reaction catalysed by enzyme phospholipase D only presence ethanol (Figure 1) [3]. Given physiopathology underlying formation degradation, astutely highlighted factors such as anaemia, cirrhosis drinking patterns may significantly influence levels [4]. However, handful studies have specifically investigated impact these conditions levels. Limited evidence suggests elimination PEth, rather than its formation, be affected alter red blood cell turnover [3, 5, 6]. Additional research required to fully address questions. Regarding patterns, has shown potential identifying excessive episodes binge behaviours, but this area warrants further investigation SLD population 7]. Notably, another important question needs addressed clearly exact quantity must consumed over specific time period yield test In conclusion, body conducted medical settings outside SLD, screening emergency departments, detoxification programs, pre-employment examinations, transplant evaluation forensic context, demonstrated reliable detecting heavy consumption [7-9]. Our study represents initial effort within setting support objective subcategories enhancing subclassification alongside self-reported use. Despite promising findings, many critical questions remain larger more diverse studies. These include establishment thresholds corresponding variability degradation across different diseases patterns. Federica Tavaglione: writing – review editing, original draft. Rohit Loomba: draft, editing. The authors' declarations personal financial interests are unchanged those article This linked Tavaglione et al papers. To view articles, visit https://doi.org/10.1111/apt.18506 https://doi.org/10.1111/apt.18529. authors nothing report.
Language: Английский
Citations
0